The largest database of trusted experimental protocols

PET protocol

PET (Positron Emission Tomography) protocols are standardized procedures used in medical imaging to visualize and quantify the distribution of positron-emitting radiopharmaceuticals within the body.
These protocols involve the administration of a radioactive tracer, typically a molecule labeled with a positron-emitting isotope, and the subsequent detection of the emitted positrons using a PET scanner.
PET protocols are widely used in the diagnosis, staging, and monitoring of a variety of diseases, including cancer, neurological disorders, and cardiovascular conditions.
They provide valuable information about physiological and metabolic processes, enabling clinicians to make informed decisions about patient care.
PubCompare.ai, an AI-driven leader in research protocol comparison and optimization, can help researchers and clinicians locate the best PET protocols from literature, pre-prints, and patents, saving time and effort.
The AI-powered comparisons offered by PubCompare.ai identify the most optimized protocols and products, enhancing the efficiency and effectiveness of PET imaging procedures.

Most cited protocols related to «PET protocol»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Amyloid Proteins CAT SCANNERS X RAY ECHO protocol Hypersensitivity PET protocol Protocol Compliance Radionuclide Imaging Reading Frames Reconstructive Surgical Procedures Scan, CT PET TRIO protein, human

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
PET protocol Radionuclide Imaging Reading Frames Strains
From February 2009 through March 2010, the study enrolled 152 individuals approaching the end of life to obtain 35 postmortem evaluations (brain autopsies) from those who received PET imaging 12 months or less prior to death. Individuals were recruited from in-patient and community hospice programs, long-term care facilities, and outpatient community health care facilities. The main inclusion criteria included a physician’s assessment that the individual was likely to die within 6 months of study enrollment, absence of any known destructive lesion in the brain (eg, stroke or tumor), and the individual’s willingness to have florbetapir-PET imaging followed by a brain autopsy at the time of death. Each participant received a brief physical, neurological, and cognitive evaluation that included assessments of memory, language, and constructional praxis. In the 35 individuals who were autopsied, the major comorbidities were hypertension (66%), cancer (49%), cardiac disease (46%), chronic lung disease (37%), and diabetes (29%). The primary study clinical diagnosis and cause of death (as noted by the study physician) are listed in TABLE 1.
The postmortem evaluations for the first 6 participants were evaluated separately as part of a preplanned interim analysis. The final 29 postmortem evaluations comprised the primary analysis data set.
A second group of 74 young cognitively normal, healthy individuals (aged 18–50 years) were recruited from the community and were evaluated using the same clinical assessment and PET imaging protocol as those in the autopsy cohort to determine (among individuals who presumably had no β-amyloid) the proportion that were categorized correctly by a florbetapir-PET scan as amyloid negative.
For all participants in this study, written informed consent was provided by the individual or by his/her designated decision maker and the study was approved by institutional review boards.
Publication 2011
Amyloid Proteins Autopsy Brain Cerebrovascular Accident Cognition Diabetes Mellitus Diagnosis Disease, Chronic Ethics Committees, Research florbetapir Heart Diseases High Blood Pressures Lung Lung Diseases Malignant Neoplasms Memory Neoplasms Patients PET protocol Physical Examination Physicians Positron-Emission Tomography
A multi-step coregistration protocol between 68Ga-HBED-CC-PSMA PET/CT and histopathology was implemented (Figure 1). In the first step, whole-mount prostate slices were coregistered to the ex-vivo CT in a manner similar to the procedure described by Grosu et al. 21 (link). We used a fixation device (localizer) consisting of a customized cuvette with 4-mm-spaced markers, filled with agarose in which the prostate was embedded and fixated. The basic edges (ventral, dorsal, left, right) of the resected prostate were marked with special ink to support orientation of the prostate in the agarose-filled cuvette. The aim was to position the prostate in a similar orientation as in in-vivo CT. After ex-vivo CT scan of the localizer, the pathologic slices were cut perpendicular to the urethra and along the localizer markers using a customized cutting device (Supplementary Figure 1). Parallel 4-mm step-sections were cut in the same angle as the ex-vivo CT slices. PCa and non-malignant tissue was delineated on each histopathological slice by an experienced pathologist. Histopathological slices were than manually matched to the ex-vivo CT, using MITK software (MITK Workbench 2014.10.00, German cancer research center, Germany) under guidance of the 4-mm grid. The contours of PCa (PCa-histo) and non PCa (NPCa-histo) were manually transferred to corresponding CT slices. In the next step, a careful manual coregistration with additional non-rigid deformation (to account for ex-vivo changes) between ex-vivo CT (including PCa-histo and NPCa-histo) and in-vivo CT was performed in MITK by two experienced specialists in consensus.
Subsequently, PCa-histo contours were used to represent the PCa distribution in a 4-mm slice. The voxels in a 3D model were set to discrete values (PCa 1, non PCa 0.1, tissue outside the prostatic gland 0) in PMOD (PMOD v3.6, PMOD Technologies, Switzerland). To account for the obvious (three orders of magnitude) difference between the resolution of PSMA-PET and histology slices for correlation analyses, a Gaussian smoothing (FWHM 7 mm) of the discretized histological data was performed to create a so called histo-PET. Subsequently, rigid mutual information (MI) coregistration between PSMA PET and histo-PET was conducted in PMOD in order to account for minor in-vivo misalignments between PET and CT (i.e. due to bladder or bowel movements) and to overcome possible uncertainties between ex- and in-vivo CT coregistration (low soft-tissue contrast in CT).
Publication 2016
Defecation gallium GA-68 gozetotide Malignant Neoplasms Medical Devices Muscle Rigidity Nasopharyngeal Carcinoma Pathologists PET protocol Prostate Sepharose Specialists Tissues Urethra Urinary Bladder X-Ray Computed Tomography
The MRI acquisition protocol is described in the supplementary material (Tables S3 and S4). Briefly, the resting‐state fMRI scans were preprocessed using the Brainnetome Toolkit (http://brant.brainnetome.org) (Xu, Liu, Zhan, Ren, & Jiang, 2018), which included the following steps: (1) slice timing correction; (2) realignment to the first volume; (3) spatial normalization to Montreal Neurological Institute (MNI) space at 2 mm × 2 mm × 2 mm; (4) regression of nuisance signals, including linear trends, six motion parameters and their first‐order differences, and signals representing white matter and cerebrospinal fluid; (5) temporal bandpass filtering (0.01–0.08 Hz) to reduce high‐frequency noise. Subsequently, any voxel where the mean absolute deviation in the fMRI signal was less than 0.05 and any area that did not have fMRI signal recorded from one or more participants was excluded (Liu et al., 2014, 2016; Zhan et al., 2016).
The cortex and subcortex were parcellated based on the Brainnetome Atlas (Fan et al., 2016). The above preprocessing steps resulted in a set of 263 regional areas of the Brainnetome Atlas, which were used in all further analyses. The 263 regions comprising the parcellation atlas based on the overlapping regions of all the individuals are listed in the supplementary material (Table S7). We derived a regional fMRI signal for each region by averaging the fMRI signal across all voxels included in the region. This process was repeated for all individuals and regions.
Additionally, the florbetapir (F18‐AV‐45) PET scans of 625 subjects (291 patients with AD and a well‐matched [age and gender] group of 334 healthy comparison individuals) were collected from ADNI for subsequent correlation analysis. The downloaded F18‐AV‐45 PET images were already preprocessed, including computation of Standardized Uptake Value Ratio (SUVR) and smoothing. A detailed description of PET protocols and acquisition procedures can be found at (http://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/). The PET images were rigidly co‐registered to the corresponding T1 images and then nonlinearly co‐registered to the standard MNI space at 2 mm × 2 mm × 2 mm by SPM12 (Statistical Parametric Mapping) software.
Publication 2020
Cerebrospinal Fluid Cortex, Cerebral florbetapir fMRI Gender Patients PET protocol Positron-Emission Tomography Radionuclide Imaging White Matter

Most recents protocols related to «PET protocol»

Maximum intensity micro-PET images were obtained on a Siemens INVEON small-animal PET/CT scanner (Siemens Medical Solutions USA, Inc., Malvern, PA). The unit has a gantry diameter of 21 cm, a transverse field of view (FOV) of 12.8 cm, and an axial length of 11.6 cm. The scanner operated in a 90 min dynamic, three-dimensional (3D) volume imaging acquisition mode. The mice were laser aligned at the center of the scanner FOV for subsequent imaging. Mice were administered 1.48–15.5 MBq (averaging ~ 7.4 MBq) of [18F]1 in 100 μL of 10% EtOH in saline containing sodium ascorbate via tail vein injection. Immediately after injection, the mice were anesthetized using a 1 L oxygen flow of 3% isoflurane and imaged within 2–5 min of injection. Micro-PET image reconstruction was obtained with an OSEM3D algorithm without tissue attenuation correction. The micro-PET data was analyzed using Siemens Inveon Research Workplace, General Analysis software.
The micro-CT images were obtained on a MILabs VECTor6CTUHROI unit (Houten, Utrecht, Netherlands) immediately after micro-PET for the purpose of anatomic/molecular data fusion. The accurate total body, full scan angle micro-CT images were acquired for ~ 8–10 min, and concurrent image reconstruction was achieved using a Hann projection filter algorithm at 100 μm voxel size. Reconstructed DICOM (digital imaging and communication in medicine) micro-CT images were created using PMOD 4.1 software and imported into the Siemens Inveon Research Workplace software for subsequent image fusion with micro-PET for the ROIs overlay to create TACs to access radioisotope uptake and distribution.
The second PET/CT scan followed the same imaging protocol as the first PET/CT scan except for the blocking agent (5 mg/kg) was administered intravenously 5 min prior to [18F]1 injection. All mice were sacrificed 24 hours following the completion of the second PET/CT scan, and their hearts and descending aortas were harvested and preserved in 4% paraformaldehyde in phosphate-buffered saline (PBS) solution until further analysis.
Full text: Click here
Publication Preprint 2023
Cardiac Arrest CAT SCANNERS X RAY Descending Aorta Ethanol Fingers Heart Human Body Isoflurane Mice, House Oxygen paraform PET protocol Pets Pharmaceutical Preparations Phosphates Radioisotopes Saline Solution Scan, CT PET Sodium Ascorbate Tail Tissues Veins X-Ray Computed Tomography X-Ray Microtomography
The study recruited all adult Saudi patients who suffered from CVD and were eligible to undergo SPECT/CT or PET/CT MPI scans between 2020 and 2021. Ethical approval (IRB log number: 21-204E) was acquired before commencing the study. The data were gathered from scans conducted on one SPECT/CT scanner and one PET/CT scanner in Riyadh, Saudi Arabia. Five SPECT/CT MPI scans were selected for this study: one-day stress/rest (99mTc-Sestamibi and 99mTc-Tetrofosmin), two-day stress/rest (99mTc-Sestamibi and 99mTc-Tetrofosmin), and stress/rest and reinjection 201Tl. For PET/CT MPI scans, one stress/rest rubidium-82 (82RB) was selected for this study. A retrospective data collection approach was implemented to collect all the required information for this project. Two NM technologists were assigned to collect all the data-based booklet questionnaires used in this study. All the required data had been registered on hospital radiology systems and picture archiving communication systems (PACS).
The first part of the data collection aspect of this study focused primarily on obtaining information on the MPI protocol used at the study facility, such as the model and brand name of the SPECT/CT and PET/CT scanners, the manufacturer, commission date, detector material, and recommended administration method for radioactivity. The second part of the LDRL audit focused on collecting individual demographic data and radiation dose information on each patient who underwent the MPI SPECT/CT and PET/CT protocols considered in this study. The demographic data include the clinical indication, gender, age, weight, and height. Radiation dose information includes the type of administered activity during each SPECT and PET examination and CT dose quantity in CTDIvol and DLP. Details on the acquisition time, matrix size, and collimator were collected for SPECT MPI scans, while scanning time and number of bed/positions was collected for PET MPI scans. CT parameters in the axillary of SPECT and PET MPI were collected, including tube rotation time, kilovoltage, scan length, pitch, and slice thickness. The data collection approach followed the non-weight restricted protocol consistent with the NDRL method for adult common SPECT/CT and PET/CT scans used in a published international study implemented by the Australian Radiation Protection and Nuclear Safety Agency [19 ].
All the CT data related to the SPECT/CT MIP scans were used for AC, and the CT portion of the PET/CT scan was used for AC-AL. The CT equipment was calibrated by the manufacturer using a 32 cm body phantom for CT components associated with all identified SPECT MPI protocols and the PET MPI protocol. Automatic exposure control software was utilised for all identified CT MPI acquisition protocols. The scanner installation data were collected in June 2012 for the SPECT/CT scanner and 2017 for the PET/CT scanner.
Regarding the statistical data analysis, all the collected data were transferred to an Excel sheet. Then, after data entry, they were transferred to SPSS software version 18.0 (PASW, Chicago, IL, USA). The LDRL value for administered activity, CTDIvol, and DLP in frameworks of SPECT/CT and PET/CT MPI were determined based on 50th percentiles. Moreover, the SPECT, PET, and CT data were analysed using descriptive statistics, such as mean, minimum, maximum, and standard deviation (SD). The SPECT and PET radiopharmaceuticals data were analysed and compared with the 50th and 75th percentiles of international published MPI data. Likewise, the CT components associated with SPECT/CT and PET/CT MPI scans were analysed and compared with 50th and 75th percentiles of published international NDRL studies.
Full text: Click here
Publication 2023
Adult Axilla CAT SCANNERS X RAY CT protocol Gender Human Body Patients PET protocol Positron-Emission Tomography Radiation Radiation Protection Radioactivity Radiography Radionuclide Imaging Radiopharmaceuticals Rubidium-82 Safety Scan, CT PET Single Photon Emission Computed Tomography Computed Tomography technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane Technetium Tc 99m Sestamibi Tomography, Emission-Computed, Single-Photon
The subjects in the amyloid cohort had the Florbetapir (18F-AV-45) injection for a PET protocol: 370 MBq (10.0 mCi) ± 10%, 20 min (4 × 5 min frames) acquisition at 50–70 min post-injection.
For each subject, all scans were collected from ADNI's image and data archive using a specific advanced search (“AV45 Coreg, Avg, Std Img and Vox Siz, Uniform Resolution”). The scans from this search were coregistered PET-MR and intensity normalized images that used Statistical Parametric Mapping (SPM8), a medical imaging process which allows SUV comparisons within select regions to be made in a given subject (Smith et al., 2022 (link)). Coregistering is important because MR has fine anatomical detail and PET cannot delineate anatomic structures (Robertson et al., 2016 (link)). PET transfers radiotracer information to MR throughout the coregistering process. Over the 20-min acquisition time, each image was resized to a uniform voxel size and each uniform size was 160 × 160 in-plane, along with 96 axial slices (Reith et al., 2020 (link); Landau et al., 2021 ). All images were normalized and rescaled to 224 × 224 to accommodate the ImageNet pretraining.
We obtained the 18F-florbetapir cortical summary SUVR (“SUMMARYSUVR_WHOLECEREBNORM”) for each scan from the UC Berkeley AV45 Analysis. This calculation required FreeSurfer processing which included skull-stripping, segmentation, and delineation of cortical and subcortical regions in MRI scans which were co-registered to PET scans using SPM8. The cortical summary region (“COMPOSITE_SUVR”) was calculated by taking the mean uptake of all SUVR values from the subregions. These SUVR (“COMPOSITE_SUVR”) values were calculated with respect to the reference region (“WHOLECEREBELLUM_SUVR”) to derive the summary SUVR value for the whole cerebellum (“SUMMARYSUVR_WHOLECEREBNORM”) for each scan (Landau et al., 2021 ).
SUV(t) represents the radioactivity concentration in the subcortical and cortical regions (ROI) averaged during a period of time over the quantity of the injected dose (kBq/mL) divided by the weight (kg). This value is then calculated with respect to the reference region which determines SUVR.
Full text: Click here
Publication 2023
18F-AV-45 Amyloid Proteins Cerebellum Coreg Cortex, Cerebral Cranium florbetapir MRI Scans PET protocol Positron-Emission Tomography Radioactivity Radionuclide Imaging Reading Frames
Using software developed in-house that runs on MATLAB (MathWorks, MA, USA), regions of interest (ROI) were automatically drawn to include the spheres and background of the phantom image according to NEMA NU2-2007 criteria. To optimize the total-body 18F-FDG PET/CT scanning protocol, the background variability (BV) and CR were considered the measures of image noise and quantitation accuracy, respectively. BV was defined by the standard deviation (SD) of 12 ROIs located at five slices (a total of 60 background ROIs of each size)—one central slice crossing the sphere center and four close slices at ± 1 cm and ± 2 cm—divided by the mean activity of these 60 background ROIs. CR was defined as follows [39 ]: CR=MH/MB-1CH/CB-1×100%, where M is the count from the PET image and C is the activity in hot spheres and background ROIs (subscripts H and B, respectively). Notably, the contrast-to-noise ratio (CNR), which is considered a key measure of PET imaging performance, is defined as CR divided by BV. First, we regrouped the subsets based on the BV value, where the upper threshold of BV was 15% [40 ]. We then calculated the CR in each filtered condition and produced the CNR that provides a quantitative measure of balance for both BV and RC with the same weight ratio [41 (link), 42 ]. A subjective method of assessment—namely the 5-point Likert scale—was also used to evaluate overall impression of image quality and image noise. All of the center slice images were independently rated by two nuclear radiologists (a senior radiologist with > 5-year experience and a junior radiologist with 1 year of experience reading PET/CT scans) in blinded. The 5-point Likert scale of overall image quality comprises five categories: (1) poor, (2) barely diagnostic, (3) clinically acceptable, (4) superior to the regular quality of daily practice, and (5) excellent. The relationship plot between the CNR value and 5-point Likert scale combines objective and subjective assessment for optimal protocol recommendation. Specifically, the protocol that generates images with high quality (e.g., a score greater than 4- on the 5-point Likert scale) and simpler acquisition settings (e.g., a shorter scan duration and lesser iterations) was preferred in this study.
To facilitate the localization of small lesions, our results—such as BV, CR, and CNR—are mainly demonstrated for hot-spheres with a diameter of 10 mm.
Full text: Click here
Publication 2023
Diagnosis F18, Fluorodeoxyglucose Human Body PET protocol Radiologist Radionuclide Imaging Scan, CT PET
We retrospectively included patients who had been evaluated and followed up in the memory clinic of the Amsterdam UMC Alzheimer center, or who participated in a multicenter AD clinical trial with central EEG analysis at the Amsterdam UMC EEGlab, between October 15, 2003, and January 1, 2019. All participants provided written informed consent for the use of their data for research purposes. Although AD represents a seamless disease continuum, patients can be assigned to progressive phases based on physical, cognitive, and functional assessments [1 (link)]. We differentiated between patients with MCI and dementia due to AD based on established clinical guidelines [40 (link)]. For a detailed description of all investigations that were performed as part of our routine diagnostic screening, see Van der Flier et al. [41 (link)]. Two or more EEG recordings were available for all participants. Recordings that were heavily contaminated with artifacts were excluded from analysis. Follow-up durations shorter than 3 months or longer than 3 years are not commonly employed in AD clinical trials. We therefore only evaluated follow-up recordings that were obtained within this time-frame. All participants were positive for Aβ deposition, as assessed using CSF Aβ42 (cut-off < 813 pg/ml, Tijms et al. (2018)) [42 ] or [11C] PiB amyloid PET investigation (the routine PET protocol has been described elsewhere [43 (link), 44 (link)]). Tau pathology and neurodegeneration were characterized at baseline using CSF p-tau (cut-off > 52 pg/ml) and t-tau levels (cut-off > 375 pg/ml) [45 (link)]. Tau and neurodegeneration positive and negative patients (T +/- , N +/-) were included in this study. Medial temporal lobe atrophy (MTA), ranging from 0 (no atrophy) to 4 (severe atrophy), was rated on coronal T1-weighted MRI images. To evaluate the potential effect of pharmacological agents (i.e., cholinesterase inhibitors, anti-depressants, anti-epileptic drugs, anti-psychotics, benzodiazepines) on our findings, medication use was evaluated and scored.
Full text: Click here
Publication 2023
Antiepileptic Agents APP protein, human Atrophy Benzodiazepines Cholinesterase Inhibitors Cognition Dementia Diagnosis Memory Mental Disorders Nerve Degeneration Patients PET protocol Pharmaceutical Preparations Physical Examination Reading Frames Temporal Lobe

Top products related to «PET protocol»

Sourced in Germany, United States
The Biograph mMR is a positron emission tomography (PET) and magnetic resonance imaging (MRI) system manufactured by Siemens. It integrates PET and MRI technologies to provide simultaneous imaging of the body. The Biograph mMR enables the acquisition of high-quality PET and MRI data in a single examination.
Sourced in Germany, United States, Netherlands, Japan
The Biograph mCT is a Positron Emission Tomography (PET) and Computed Tomography (CT) system manufactured by Siemens. It is designed to provide high-quality imaging for clinical and research applications. The core function of the Biograph mCT is to acquire and analyze PET and CT scans simultaneously, allowing for accurate anatomical and functional information to be obtained.
Sourced in United States, United Kingdom, Netherlands
The Discovery STE is a medical imaging system designed for Positron Emission Tomography (PET) and Computed Tomography (CT) scans. It combines PET and CT modalities to provide high-quality images for diagnostic and clinical applications.
Sourced in Germany, United States
The Biograph 40 is a positron emission tomography (PET) scanner manufactured by Siemens. It is designed to acquire high-quality images of the human body for medical diagnostic purposes. The core function of the Biograph 40 is to detect and measure the distribution of radioactive tracer substances within the body, which can provide valuable information about the physiological and metabolic processes occurring in various organs and tissues.
Sourced in United States, Germany
The Discovery LS is a laboratory equipment product manufactured by GE Healthcare. It is designed to provide high-quality imaging capabilities for a variety of research and clinical applications. The core function of the Discovery LS is to capture and analyze images using advanced imaging technologies.
Sourced in Germany, United States, Japan
The Biograph 16 is a medical imaging device designed for computed tomography (CT) scanning. It features a 16-slice configuration, allowing for the capture of high-resolution images of the human body. The core function of the Biograph 16 is to provide healthcare professionals with detailed anatomical information to support clinical decision-making and patient care.
Sourced in United States, United Kingdom, Japan
The Discovery ST is a general-purpose imaging system designed for scientific research and clinical applications. It offers high-quality imaging capabilities to support a wide range of applications. The system provides precise and reliable performance to meet the needs of modern laboratories and healthcare facilities.
Sourced in United States
The Discovery RX is a laboratory equipment product offered by GE Healthcare. It is designed to perform basic analytical tasks in a clinical laboratory setting. The core function of the Discovery RX is to enable reliable and efficient data collection and analysis for researchers and healthcare professionals.
Sourced in Germany, United States, United Kingdom
The Inveon Research Workplace is a comprehensive small-animal imaging platform designed for preclinical research. It integrates multiple imaging modalities, including PET, SPECT, CT, and optical imaging, into a single system. The Inveon Research Workplace allows researchers to acquire high-quality, co-registered images for a wide range of small-animal applications.
Sourced in United States
The Inveon dedicated small-animal PET scanner is a research-grade imaging device designed for the visualization and quantification of biological processes in small animals. It provides high-resolution positron emission tomography (PET) imaging capabilities for preclinical studies.

More about "PET protocol"

Positron Emission Tomography (PET) is a powerful medical imaging technique that allows clinicians to visualize and quantify the distribution of positron-emitting radiopharmaceuticals within the body.
PET protocols are standardized procedures that involve the administration of a radioactive tracer, typically a molecule labeled with a positron-emitting isotope, and the subsequent detection of the emitted positrons using a PET scanner.
These protocols are widely used in the diagnosis, staging, and monitoring of a variety of diseases, including cancer, neurological disorders, and cardiovascular conditions.
PET imaging provides valuable information about physiological and metabolic processes, enabling clinicians to make informed decisions about patient care.
PubCompare.ai, an AI-driven leader in research protocol comparison and optimization, can help researchers and clinicians locate the best PET protocols from literature, pre-prints, and patents, saving time and effort.
The AI-powered comparisons offered by PubCompare.ai identify the most optimized protocols and products, enhancing the efficiency and effectivness of PET imaging procedures.
PET imaging can be performed using a variety of PET scanners, including the Biograph mMR, Biograph mCT, Discovery STE, Biograph 40, Discovery LS, Biograph 16, Discovery ST, Discovery RX, and Inveon Research Workplace.
These scanners are designed to provide high-quality images and accurate quantification of tracer uptake, enabling clinicians to make informed decisions about patient care.
The Inveon dedicated small-animal PET scanner is also a valuable tool for preclinical research, allowing researchers to study the effects of drugs and other interventions on animal models.
OtherTerms: Positron Emission Tomography, PET, radiopharmaceuticals, medical imaging, diagnostic, disease monitoring, cancer, neurological disorders, cardiovascular conditions, physiology, metabolism, optimization, Biograph, Discovery, Inveon